[go: up one dir, main page]

SMT202000224T1 - Vettore genico - Google Patents

Vettore genico

Info

Publication number
SMT202000224T1
SMT202000224T1 SM20200224T SMT202000224T SMT202000224T1 SM T202000224 T1 SMT202000224 T1 SM T202000224T1 SM 20200224 T SM20200224 T SM 20200224T SM T202000224 T SMT202000224 T SM T202000224T SM T202000224 T1 SMT202000224 T1 SM T202000224T1
Authority
SM
San Marino
Prior art keywords
gene vector
gene
vector
Prior art date
Application number
SM20200224T
Other languages
English (en)
Inventor
Alessandra Biffi
Bernhard Rudolf Gentner
Luigi Naldini
Original Assignee
Ospedale San Raffaele Srl
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele Srl, Fond Telethon filed Critical Ospedale San Raffaele Srl
Publication of SMT202000224T1 publication Critical patent/SMT202000224T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/51Physical structure in polymeric form, e.g. multimers, concatemers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SM20200224T 2009-04-30 2010-04-30 Vettore genico SMT202000224T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17412409P 2009-04-30 2009-04-30
PCT/IB2010/001166 WO2010125471A2 (en) 2009-04-30 2010-04-30 Gene vector
EP10723305.8A EP2424571B1 (en) 2009-04-30 2010-04-30 Gene vector

Publications (1)

Publication Number Publication Date
SMT202000224T1 true SMT202000224T1 (it) 2020-05-08

Family

ID=42790671

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200224T SMT202000224T1 (it) 2009-04-30 2010-04-30 Vettore genico

Country Status (23)

Country Link
US (4) US10287579B2 (it)
EP (2) EP3733214A1 (it)
JP (2) JP6144911B2 (it)
KR (1) KR101793615B1 (it)
CN (1) CN102596255B (it)
AU (1) AU2010243276B2 (it)
BR (1) BRPI1010873B1 (it)
CA (1) CA2759438C (it)
CY (1) CY1123218T1 (it)
DK (1) DK2424571T3 (it)
EA (1) EA023938B1 (it)
ES (1) ES2786039T3 (it)
HR (1) HRP20200647T1 (it)
HU (1) HUE049845T2 (it)
IL (1) IL215804A (it)
LT (1) LT2424571T (it)
MX (1) MX2011011508A (it)
PL (1) PL2424571T3 (it)
PT (1) PT2424571T (it)
SG (2) SG10201610827RA (it)
SI (1) SI2424571T1 (it)
SM (1) SMT202000224T1 (it)
WO (1) WO2010125471A2 (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1010873B1 (pt) * 2009-04-30 2020-04-14 Fond Centro San Raffaele Del Monte Tabor usos de um vetor de genes, de uma composição farmacêutica e de uma célula
LT3351636T (lt) 2010-05-14 2020-10-12 Oregon Health & Science University Rekombinantiniai žcmv ir rhcmv vektoriai koduojami heterologiniu antigenu, išskirtu iš paramyxoviridae viruso ir jų panaudojimas
EP2591095B1 (en) * 2010-07-08 2016-04-27 Duke University Direct reprogramming of cells to cardiac myocyte fate
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20150190532A1 (en) * 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
CA2872241C (en) 2012-05-25 2022-12-06 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス, インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
ES2653212T3 (es) 2012-12-06 2018-02-06 Sigma Aldrich Co. Llc Modificación y regulación del genoma en base a CRISPR
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
CN106062201B (zh) 2013-10-24 2020-11-06 圣拉法埃莱医院有限公司 方法
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
JP6960159B6 (ja) * 2015-04-22 2022-06-24 国立大学法人京都大学 組織細胞の選別方法
WO2016201507A1 (en) * 2015-06-15 2016-12-22 Murdoch Childrens Research Institute Method of measuring chimerism
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US10188750B1 (en) * 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第viii因子遺伝子
GB201612214D0 (en) 2016-07-14 2016-08-31 Univ Oxford Innovation Ltd Method
US10457940B2 (en) * 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CR20190205A (es) * 2016-10-18 2020-01-07 Univ Oregon Health & Science Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e
CN106566838B (zh) * 2016-11-14 2019-11-01 上海伯豪生物技术有限公司 一种基于CRISPR-Cas9技术的miR-126全长基因敲除试剂盒及其应用
IL320674A (en) * 2017-04-21 2025-07-01 Ospedale San Raffaele Srl Garden care
IT201700086403A1 (it) * 2017-07-27 2019-01-27 Univ Del Piemonte Orientale Endothelial-specific promoter sequences and uses thereof
KR20250040746A (ko) 2017-08-09 2025-03-24 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
SG11202101157VA (en) 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
EP3891289A2 (en) 2018-12-06 2021-10-13 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
WO2021097109A1 (en) * 2019-11-12 2021-05-20 The Regents Of The University Of California Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous disease
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
AU2021330936A1 (en) 2020-08-23 2023-05-04 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
JP2024532262A (ja) 2021-08-23 2024-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第viii因子遺伝子
EP4392566A2 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Baculovirus expression system
CN115725656A (zh) * 2021-09-01 2023-03-03 联邦生物科技(珠海横琴)有限公司 一种以细胞质rna病毒为载体递送干扰rna的方法
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
MA71632A (fr) * 2022-07-25 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour l'expression sélective de cellules

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DK0968182T3 (da) 1996-08-07 2004-08-16 Darwin Discovery Ltd Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CN1606456A (zh) * 2001-10-02 2005-04-13 克雷顿研究院 限制性表达慢病毒载体
EP2290074B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
US20060134784A1 (en) * 2004-11-30 2006-06-22 Basch Ross S Methods and compositions for the growth and maintenance of stem cells
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
CA2610702A1 (en) 2005-06-03 2006-12-07 Michael Zenon Michael Targeting cells with altered microrna expression
US20090180989A1 (en) * 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
ES2557411T3 (es) 2006-01-05 2016-01-25 The Ohio State University Research Foundation Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos
US20080095750A1 (en) 2006-05-10 2008-04-24 Pennington Biomedical Research Center, Louisiana State University System Use of adipose-derived stem cells for treatment of leukodystrophies
ATE534738T1 (de) 2006-12-08 2011-12-15 Asuragen Inc Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
PT2158322T (pt) 2007-06-06 2017-08-09 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
DK2364362T3 (en) 2008-11-12 2016-01-25 Ospedale San Raffaele Srl Gene vector FOR INDUCTION OF IMMUNE TOLERANCE transgene
BRPI1010873B1 (pt) 2009-04-30 2020-04-14 Fond Centro San Raffaele Del Monte Tabor usos de um vetor de genes, de uma composição farmacêutica e de uma célula

Also Published As

Publication number Publication date
KR20120038403A (ko) 2012-04-23
JP6144911B2 (ja) 2017-06-07
SG175839A1 (en) 2011-12-29
US20120128643A1 (en) 2012-05-24
US11407996B2 (en) 2022-08-09
DK2424571T3 (da) 2020-05-04
US10287579B2 (en) 2019-05-14
IL215804A0 (en) 2012-01-31
WO2010125471A3 (en) 2010-12-29
JP6370278B2 (ja) 2018-08-08
EP2424571B1 (en) 2020-04-08
MX2011011508A (es) 2012-02-13
SG10201610827RA (en) 2017-02-27
US20190367911A1 (en) 2019-12-05
BRPI1010873B1 (pt) 2020-04-14
PT2424571T (pt) 2020-05-06
EP3733214A1 (en) 2020-11-04
US20180044670A1 (en) 2018-02-15
AU2010243276B2 (en) 2016-09-15
JP2012525141A (ja) 2012-10-22
US20220333103A1 (en) 2022-10-20
CY1123218T1 (el) 2021-10-29
LT2424571T (lt) 2020-08-10
KR101793615B1 (ko) 2017-11-03
HRP20200647T1 (hr) 2020-10-02
SI2424571T1 (sl) 2020-10-30
EA201171335A1 (ru) 2012-05-30
ES2786039T3 (es) 2020-10-08
CN102596255A (zh) 2012-07-18
PL2424571T3 (pl) 2020-10-19
HUE049845T2 (hu) 2020-10-28
CN102596255B (zh) 2017-10-13
IL215804A (en) 2016-10-31
CA2759438C (en) 2021-03-30
JP2016028582A (ja) 2016-03-03
EP2424571A2 (en) 2012-03-07
BRPI1010873A2 (pt) 2016-03-15
EA023938B1 (ru) 2016-07-29
US9951328B2 (en) 2018-04-24
CA2759438A1 (en) 2010-11-04
AU2010243276A1 (en) 2011-11-17
WO2010125471A2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
IL215804A0 (en) Gene vector
ZA201202407B (en) Photobioreactor
GB201103481D0 (en) No details
EP2380416A4 (en) CARRYING CASE
GB201016096D0 (en) No details
GB201016097D0 (en) No details
ZA201206766B (en) Lance
GB201007384D0 (en) Enzymes
GB201118187D0 (en) Photobioreactor
PL2464939T3 (pl) Udoskonalony nośnik przedmiotu obrabianego
GB0810912D0 (en) Vector
PT2274422T (pt) Vetor de expressão
PL2664278T3 (pl) Lancet
GB0914596D0 (en) Improved hatchcover
GB201004475D0 (en) Gene silencing
GB0903658D0 (en) Antimicobial coatings
GB0908435D0 (en) Processes
GB0910833D0 (en) Avian genes
PL2393603T3 (pl) Lanca
GB0810154D0 (en) Expression vector
IL208602A0 (en) Mezuzah case
GB201105987D0 (en) Enzymes
GB0914134D0 (en) Novel genes
GB201010471D0 (en) Gene variant
GB201021720D0 (en) Gene variant